MCID: 48X005
MIFTS: 39

48,xyyy

Categories: Fetal diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for 48,xyyy

Summaries for 48,xyyy

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 99329DefinitionA rare Y chromosome number anomaly that affects only males and is characterized by mild-moderate developmental delay (especially speech), normal to mild intellectual disability, large, irregular teeth with poor enamel, tall stature and acne. Radioulnar synostosis and clinodactyly have also been associated. Boys generally present normal genitalia, while hypogonadism and infertility is frequently reported in adult males.Visit the Orphanet disease page for more resources.

MalaCards based summary : 48,xyyy, also known as 48,xyyy syndrome, is related to 47,xyy and radioulnar synostosis, nonsyndromic. The drugs Linagliptin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and prostate, and related phenotypes are high palate and short neck

Related Diseases for 48,xyyy

Diseases related to 48,xyyy via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 47,xyy 10.4
2 radioulnar synostosis, nonsyndromic 10.2
3 hypogonadotropic hypogonadism 10.1
4 synostosis 10.1
5 radioulnar synostosis 10.1
6 horseshoe kidney 10.1

Graphical network of the top 20 diseases related to 48,xyyy:



Diseases related to 48,xyyy

Symptoms & Phenotypes for 48,xyyy

Human phenotypes related to 48,xyyy:

58 31 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 high palate 58 31 hallmark (90%) Very frequent (99-80%) HP:0000218
2 short neck 58 31 hallmark (90%) Very frequent (99-80%) HP:0000470
3 global developmental delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001263
4 depressed nasal bridge 58 31 hallmark (90%) Very frequent (99-80%) HP:0005280
5 hypertelorism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000316
6 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
7 pes planus 58 31 hallmark (90%) Very frequent (99-80%) HP:0001763
8 intellectual disability, mild 58 31 hallmark (90%) Very frequent (99-80%) HP:0001256
9 thick lower lip vermilion 58 31 hallmark (90%) Very frequent (99-80%) HP:0000179
10 recurrent upper respiratory tract infections 58 31 hallmark (90%) Very frequent (99-80%) HP:0002788
11 acne 58 31 hallmark (90%) Very frequent (99-80%) HP:0001061
12 abnormal dermatoglyphics 58 31 hallmark (90%) Very frequent (99-80%) HP:0007477
13 epicanthus 58 31 hallmark (90%) Very frequent (99-80%) HP:0000286
14 azoospermia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000027
15 long philtrum 58 31 hallmark (90%) Very frequent (99-80%) HP:0000343
16 asthma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002099
17 radioulnar synostosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002974
18 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
19 feeding difficulties 58 31 hallmark (90%) Very frequent (99-80%) HP:0011968
20 dislocated radial head 58 31 hallmark (90%) Very frequent (99-80%) HP:0003083
21 aggressive behavior 58 31 hallmark (90%) Very frequent (99-80%) HP:0000718
22 abnormal renal morphology 58 31 hallmark (90%) Very frequent (99-80%) HP:0012210
23 low frustration tolerance 58 31 hallmark (90%) Very frequent (99-80%) HP:0000744
24 male hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000026
25 impulsivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0100710
26 primary gonadal insufficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0008193
27 hypoplasia of dental enamel 58 31 hallmark (90%) Very frequent (99-80%) HP:0006297
28 irregularly spaced teeth 58 31 hallmark (90%) Very frequent (99-80%) HP:0006316
29 intellectual disability 58 Very frequent (99-80%)
30 behavioral abnormality 58 Very frequent (99-80%)
31 abnormality of the foot 58 Very frequent (99-80%)

Drugs & Therapeutics for 48,xyyy

Drugs for 48,xyyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Tocopherol Approved, Investigational Phase 4 1406-66-2
3
Eplerenone Approved Phase 4 107724-20-9 150310 443872
4
Amantadine Approved Phase 4 768-94-5 2130
5
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
6
Nalbuphine Approved Phase 4 20594-83-6 5360630 5311304
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Lincomycin Approved, Vet_approved Phase 4 154-21-2 656509
9
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
10
rituximab Approved Phase 4 174722-31-7 10201696
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
12
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
13
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
14
Zidovudine Approved Phase 4 30516-87-1 35370
15
Etravirine Approved Phase 4 269055-15-4 193962
16
Methadone Approved Phase 4 76-99-3 4095
17
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
18
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
19
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
24
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
25
Infliximab Approved Phase 4 170277-31-3
26
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
27
Misoprostol Approved Phase 4 59122-46-2 5282381
28
Montelukast Approved Phase 4 158966-92-8 5281040
29
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
30
Didanosine Approved Phase 4 69655-05-6 50599
31
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
32
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
33
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
34
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
35
Voriconazole Approved Phase 4 137234-62-9 71616
36
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
37
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
38
Iron Approved Phase 4 7439-89-6 23925 29936
39
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
40
Tapentadol Approved Phase 4 175591-23-8 9838022
41
Vancomycin Approved Phase 4 1404-90-6 441141 14969
42
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
43
Insulin glargine Approved Phase 4 160337-95-1
44
Insulin lispro Approved Phase 4 133107-64-9
45
Ondansetron Approved Phase 4 99614-02-5 4595
46
Omalizumab Approved, Investigational Phase 4 242138-07-4
47
Budesonide Approved Phase 4 51333-22-3 63006 5281004
48
alemtuzumab Approved, Investigational Phase 4 216503-57-0
49
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
50
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534

Interventional clinical trials:

(show top 50) (show all 2620)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
2 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
3 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
4 Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit. Unknown status NCT01883596 Phase 4 0.12% chlorhexidine solution;Placebo
5 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
6 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
7 Effects of Linagliptin and Metformin Monotherapy or Combined Sequential Treatment After Early Short-term Intensive Insulin Treatment on Long-term Blood Glucose Control and Function of β Cells in Patients With Type 2 Diabetes Unknown status NCT03194945 Phase 4 CSII followed by Lina+MET;CSII followed by Lina;CSII followed by MET;CSII alone
8 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
9 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
10 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
11 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
12 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone. Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
13 A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH) Unknown status NCT00699465 Phase 4 enoxaparin;enoxaparin placebo
14 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
15 Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
16 Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery. Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
17 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
18 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
19 Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy Unknown status NCT01893788 Phase 4 Aliskiren;Eplerenone
20 The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial Unknown status NCT00841243 Phase 4
21 Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically Unknown status NCT02355093 Phase 4 ropivacaine
22 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
23 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
24 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
25 A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement Unknown status NCT00354445 Phase 4 pegaptanib sodium (Macugen)
26 Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
27 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
28 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
29 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
30 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
31 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
32 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
33 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
34 Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks Unknown status NCT02470650 Phase 4 elvitegravir/cobicistat/emtricitabine/tenofovir;Darunavir;abacavir/lamivudine;Ritonavir;Lamivudine;rilpivirine
35 A Randomized Controlled Trial to Compare the Efficacy and Safety of NALDEBAIN With Intravenous Patient-Controlled Analgesia With Fentanyl for the Treatment of Post-Laparotomy Surgery Unknown status NCT03296488 Phase 4 Nalbuphine Sebacate;Fentanyl Citrate
36 A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides Unknown status NCT02644538 Phase 4 PegIFN alfa-2a
37 An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4 Sirolimus;Tacrolimus
38 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children Unknown status NCT01944189 Phase 4
39 An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir(RAL)in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
40 A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis Unknown status NCT01876628 Phase 4 Flucloxacillin and Clindamycin;Flucloxacillin and placebo
41 A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
42 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
43 Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study Unknown status NCT03793205 Phase 4 Long-acting G-CSF;Short-acting G-CSF
44 The Effectiveness, Safety, and Acceptability of Home-administered Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks: A Prospective Cohort Study in Mexico City Unknown status NCT02745093 Phase 4 Mifepristone;Misoprostol
45 A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients Unknown status NCT03448744 Phase 4 Thymosin Alpha1;Entecavir
46 Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
47 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis Unknown status NCT00624091 Phase 4
48 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
49 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
50 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo

Search NIH Clinical Center for 48,xyyy

Genetic Tests for 48,xyyy

Anatomical Context for 48,xyyy

MalaCards organs/tissues related to 48,xyyy:

40
Liver, Endothelial, Prostate, Skin, Kidney, Spinal Cord, Bone

Publications for 48,xyyy

Articles related to 48,xyyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway. 61
33416009 2021
2
A genome-wide survey of interaction between rice and Magnaporthe oryzae via microarray analysis. 61
33356807 2021
3
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. 61
33308425 2021
4
Immediate Effect of Ankle Mobilization on Range of Motion, Dynamic Knee Valgus, and Knee Pain in Women With Patellofemoral Pain and Ankle Dorsiflexion Restriction: A Randomized Controlled Trial With 48-Hour Follow-Up. 61
33373976 2021
5
Impact of germination on phenolic composition, antioxidant properties, antinutritional factors, mineral content and Maillard reaction products of malted quinoa flour. 61
33418417 2021
6
Forecasting individual risk for long-term Posttraumatic Stress Disorder in emergency medical settings using biomedical data: A machine learning multicenter cohort study. 61
33553513 2021
7
Analyses of microRNAs and transcriptomes in the midgut of Spodoptera litura feeding on Brassica juncea. 61
32166878 2021
8
Changes to hepatic nutrient dynamics and energetics in rainbow trout (Oncorhynchus mykiss) following exposure to and recovery from hydraulic fracturing flowback and produced water. 61
33127144 2021
9
Efficacy of atrazine pesticide reduction in aqueous solution using activated carbon, ozone and a combination of both. 61
33385651 2021
10
Matrix composition during ozonation of N-containing substances may influence the acute toxicity towards Daphnia magna. 61
33129546 2021
11
COVID-19 screening test by using random oropharyngeal saliva. 61
33393672 2021
12
Selective-cerebral-hypothermia-induced neuroprotection against-focal cerebral ischemia/reperfusion injury is associated with an increase in SUMO2/3 conjugation. 61
33539797 2021
13
Effects of Good Pain Management (GPM) ward program on patterns of care and pain control in patients with cancer pain in Taiwan. 61
32803728 2021
14
Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells. 61
32557113 2021
15
Holmium phosphate nanoparticles as negative contrast agents for high-field magnetic resonance imaging: Synthesis, magnetic relaxivity study and in vivo evaluation. 61
33360885 2021
16
Data on DNA-seq analysis of Endophytic Streptomyces sp. SUK 48. 61
33604422 2021
17
Impact of a Family Economic Intervention (Bridges) on Health Functioning of Adolescents Orphaned by HIV/AIDS: A 5-Year (2012-2017) Cluster Randomized Controlled Trial in Uganda. 61
33476237 2021
18
Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. 61
32943389 2021
19
Influence of the flooded time on the performance of a tidal flow constructed wetland treating urban stream water. 61
33248753 2021
20
Feasibility assessment of outpatient colorectal resections at a tertiary referral center. 61
33094353 2021
21
Timing and Type of Venous Thromboembolic Prophylaxis in Isolated Severe Liver Injury Managed Non-Operatively. 61
33211165 2021
22
Environmental persistence of equid herpesvirus type-1. 61
32557765 2021
23
Association of fibre degradation with ruminal dissolved hydrogen in growing beef bulls fed with two types of forages. 61
32718369 2021
24
Characterizing imidacloprid and metabolites in songbird blood with applications for diagnosing field exposures. 61
33218798 2021
25
Predicting Functional Outcomes and Length of Stay Following Acoustic Neuroma Resection. 61
32757415 2021
26
Antisclerothic effect of tibolone by reducing proinflammatory cytokines expression, ROS production and LDL-ox uptake in THP-1 macrophages. 61
33383063 2021
27
Determination of Cerebrovascular Accident Predictors in Patients with New-Onset Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. 61
33450607 2021
28
Depressed Older Patients with Death Wishes: Experimental Evidence for Psychotherapists' Age and Health Bias. 61
33275085 2021
29
Clinical Presentation and Outcome of Patients With Spontaneous Coronary Artery Dissection Versus Atherosclerotic Coronary Plaque Dissection. 61
32657974 2021
30
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. 61
32351164 2021
31
Comparison of conventional autopsy with post-mortem magnetic resonance, computed tomography in determining the cause of unexplained death. 61
33464532 2021
32
Ultrasound assessment of the cervix in predicting successful membrane sweeping: a prospective observational study. 61
31092080 2021
33
Contribution of perfusion to the 11 C-acetate signal in brown adipose tissue assessed by DCE-MRI and 68 Ga-DOTA PET in a rat model. 61
33010059 2021
34
Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. 61
32885992 2021
35
Impaired interferon-α expression in plasmacytoid dendritic cells in asthma. 61
33236850 2021
36
The association between ozone and years of life lost from stroke, 2013-2017: A retrospective regression analysis in 48 major Chinese cities. 61
33092875 2021
37
Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke. 61
33274689 2021
38
Ambient sulfur dioxide and years of life lost from stroke in China: a time-series analysis in 48 cities. 61
33183785 2021
39
Ventricular arrhythmias in Takotsubo Syndrome: incidence, predictors and clinical outcomes. 61
32890232 2021
40
Prognosis and Circumferential Margin in Patients with Resected Hilar Cholangiocarcinoma. 61
32914390 2021
41
Masculinization in common carp (Cyprinus carpio) by androgen immersion: The interaction effect of hormone concentration and immersion time. 61
32901653 2021
42
Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. 61
33053388 2021
43
Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure. 61
33002568 2021
44
Pediatric Feeding Disorder in Children With Short Bowel Syndrome. 61
33003167 2021
45
Prognostic value of pretreatment plasma D-dimer level in dogs with intermediate to high-grade non-Hodgkin lymphoma. 61
32643242 2021
46
Recovery of Inflammation, Cardiac, and Muscle Damage Biomarkers After Running a Marathon. 61
31045685 2021
47
Magnetic resonance imaging differentiates locoregional flaps from free flaps after reconstructive surgical treatment of tongue cancer. 61
32855103 2021
48
Multi-sample measurement of hyperpolarized pyruvate-to-lactate flux in melanoma cells. 61
33314422 2021
49
Relationship between detection of hepatitis B virus in saliva and periodontal disease in hepatitis B virus carriers in Japan. 61
33183962 2021
50
COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. 61
32914200 2021

Variations for 48,xyyy

Expression for 48,xyyy

Search GEO for disease gene expression data for 48,xyyy.

Pathways for 48,xyyy

GO Terms for 48,xyyy

Sources for 48,xyyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....